Related Experiment Video
Updated: May 26, 2026

In Vitro SUMOylation Assay to Study SUMO E3 Ligase Activity
Published on: January 29, 2018
A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis
Jessica D Kessler1, Kristopher T Kahle, Tingting Sun
1Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Abstract:
Myc is an oncogenic transcription factor frequently dysregulated in human cancer. To identify pathways supporting the Myc oncogenic program, we used a genome-wide RNA interference screen to search for Myc-synthetic lethal genes and uncovered a role for the SUMO-activating enzyme (SAE1/2). Loss of SAE1/2 enzymatic activity drives synthetic lethality with Myc. Inactivation of SAE2 leads to mitotic catastrophe and cell death upon Myc hyperactivation. Mechanistically, SAE2 inhibition switches a transcriptional subprogram of Myc from activated to repressed. A subset of these SUMOylation-dependent Myc switchers (SMS genes) is required for mitotic spindle function and to support the Myc oncogenic program. SAE2 is required for growth of Myc-dependent tumors in mice, and gene expression analyses of Myc-high human breast cancers suggest that low SAE1 and SAE2 abundance in the tumors correlates with longer metastasis-free survival of the patients. Thus, inhibition of SUMOylation may merit investigation as a possible therapy for Myc-driven human cancers.
Insights
Targeting the SUMO-activating enzyme (SAE1/2) causes synthetic lethality in Myc-driven cancers. Inhibiting SAE1/2 disrupts Myc
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Myc is a key oncogenic transcription factor often dysregulated in human cancers.
- Identifying pathways that support the Myc oncogenic program is crucial for developing targeted therapies.
Purpose of the Study:
- To identify genes that are synthetically lethal with Myc using a genome-wide RNA interference screen.
- To investigate the role of the SUMO-activating enzyme (SAE1/2) in Myc-driven cancers.
Main Methods:
- Genome-wide RNA interference screen to identify Myc-synthetic lethal genes.
- Inactivation of SAE2 to observe effects on Myc hyperactivation.
- Analysis of SUMOylation-dependent Myc switchers (SMS genes) and their role in mitotic spindle function.
- Assessment of SAE2 requirement for Myc-dependent tumor growth in mice.
- Gene expression analysis of Myc-high human breast cancers.
Main Results:
- A role for the SUMO-activating enzyme (SAE1/2) was uncovered as a Myc-synthetic lethal gene.
- Loss of SAE1/2 enzymatic activity leads to synthetic lethality with Myc.
- Inactivation of SAE2 causes mitotic catastrophe and cell death upon Myc hyperactivation.
- SAE2 inhibition switches Myc's transcriptional program from activation to repression.
- A subset of SUMOylation-dependent Myc switchers (SMS genes) is essential for mitotic spindle function and the Myc oncogenic program.
- SAE2 is required for the growth of Myc-dependent tumors in mice.
- Low SAE1 and SAE2 abundance in human breast cancers correlates with longer metastasis-free survival.
Conclusions:
- Inhibition of SUMOylation, specifically targeting SAE1/2, presents a potential therapeutic strategy for Myc-driven cancers.
- Understanding the SUMOylation-dependent Myc switch mechanism offers insights into cancer biology.
- Targeting SAE1/2 may be a promising avenue for treating Myc-dependent human malignancies.
More Related Videos
Related Concept Videos
Induced Pluripotent Stem Cells
Somatic cells are...
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Somatic to iPS Cell Reprogramming
Combinatorial Gene Control
The expression of more than 30,000 genes is controlled by approximately 2000-3000 transcription factors. This is possible because a single transcription factor can recognize more than one regulatory sequence. The specificity in gene...

